A milestone in protection from influenza was reached with FDA approval for Novartis to manufacture seasonal influenza vaccine using cell-based technology in a US facility
|

A milestone in protection from influenza was reached with FDA approval for Novartis to manufacture seasonal influenza vaccine using cell-based technology in a US facility

On Nov. 20, 2012, the FDA approved a seasonal flu vaccine produced by Novartis using animal cell culture…